FDA News

FDA awards $18 million to fund trials of medical products for rare diseases

September 29, 2018
The FDA awarded more than $18 million in grants over the next 4 years to fund clinical trials of medical products intended to treat patients with…

FDA News

FDA approves Rituxan for pemphigus vulgaris

June 8, 2018
The FDA has approved rituximab for the treatment of adult patients with moderate-to-severe pemphigus vulgaris, a rare autoimmune blistering disease…

Meeting News

IAS 2018: Advances, collaboration in immune-mediated inflammatory diseases

April 26, 2018
BOSTON — Rheumatologists, gastroenterologists, dermatologists, immunologists and other health care providers who care for patients with…

FDA News

FDA declines proposed Rituxan, Herceptin biosimilars from Celltrion

April 6, 2018
The FDA has rejected approval of Celltrion’s biologics license applications for Truxima, a proposed rituximab biosimilar, and Herzuma, a…

In the Journals

Stem cell transplant improves overall, event-free survival in scleroderma

January 3, 2018
Myeloablative autologous stem cell transplantation improved long-term clinical outcomes, including overall survival and event-free survival, among…

In the Journals

Pneumocystis prophylaxis may be unnecessary in autoimmune blistering diseases

September 11, 2017
One patient in a large cohort of individuals with autoimmune blistering diseases developed pneumocystis pneumonia, suggesting that routine…

In the Journals

Enanthemas commonly observed in non-classic pityriasis rosea

August 15, 2017
Enanthemas were commonly reported among patients with non-classic forms of pityriasis rosea, including persistent and pediatric forms of the disease…

In the Journals

Two histopathologic patterns found in cutaneous lupus of the scalp

August 14, 2017
Histopathologic assessment of hair follicles in patients with chronic cutaneous lupus erythematosus of the scalp revealed two distinct patterns…

Phase 3 trial of Actemra for systemic sclerosis completes enrollment

August 11, 2017
This week, Genentech announced its phase 3 trial of Actemra for patients with systemic sclerosis has completed enrollment. The study will compare the…

Top five dermatology stories in July include psoriasis studies, FDA approval

July 31, 2017
Study results reporting that nail findings distinguished patients with psoriatic arthritis from those with psoriasis without arthritis was among the…

In the Journals

Immunotherapy for lung cancer leads to hair repigmentation

July 13, 2017
Patients with lung cancer who were received immunotherapy experienced hair repigmentation, with the majority also experiencing good clinical…

Week's top dermatology reads include Cimzia study, FDA actions

April 3, 2017
Study results showing minimal to no transfer of Cimzia from mother's plasma to breast milk was a top-read article of the past week on…

Recent FDA actions in dermatology include psoriasis, nasolabial fold treatments

March 31, 2017
Recent FDA actions have included approving Juvéderm Vollure XC for treating nasolabial folds with results up to 18 months and the addition of…

Meeting NewsVideo

VIDEO: Amy J. McMichael MD, FAAD, discusses Skin of Color Society

March 30, 2017
ORLANDO, Fla. — In a video perspective from the American Academy of Dermatology Annual Meeting, Amy J. McMichael, MD, FAAD, discusses…

Meeting News Coverage

AAD elects vice president-elect, board members

March 30, 2017
The American Academy of Dermatology announced the results of its annual election, including Jane M. Grant-Kels, MD, FAAD, as vice president-elect…

Meeting News

Hruza elected AAD president-elect

March 29, 2017
The American Academy of Dermatology announced that George J. Hruza, MD, MBA, FAAD, has been elected president-elect of the academy. Hruza, a…

In the Journals

Increased insulin resistance found in patients with mild lupus

March 24, 2017
Patients with mild lupus had increased insulin resistance and hyperglucagonemia, while having normal glucose tolerance and a preserved beta-cell…

FDA News

FDA grants breakthrough therapy designation to Rituxan for pemphigus vulgaris

March 24, 2017
The FDA has granted breakthrough therapy designation status to Rituxan for treating pemphigus vulgaris, Genentech has announced. Pemphigus vulgaris…

Meeting NewsVideo

VIDEO: AAD president outlines his vision for academy

March 17, 2017
ORLANDO, Fla. — In a video perspective from the American Academy of Dermatology Annual Meeting, AAD President Henry W. Lim, MD

Meeting NewsVideo

VIDEO: Highlights of AAD Therapeutic Hotline session

March 16, 2017
ORLANDO, Fla. — In a video perspective from the American Academy of Dermatology Annual Meeting, Seemal R. Desai, MD, FAAD, discusses…

Healio Jobs